# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 111-120 of 2216 results.
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
Status: Recruiting
Last Changed: Sep 02, 2020
First Received: Oct 12, 2018
Disease(s): Relapsed/Refractory Large B-cell Lymphoma
Intervention(s): Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Locations: Stanford Cancer Institute, Palo Alto, California, United States
UCLA Hematology/ Oncology, Santa Monica, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
... and 2 other locations.
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: May 30, 2019
First Received: Dec 17, 2018
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): TQB2303, Rituximab
Locations: No.150 Haping Road, Nangang District, Haerbin, Heilongjiang, China
No. 42 Baiziting Road, Xuanwu District, Nanjing, Jiangsu, China
No.8 Jiangtan Road,Weibin District, Baoji, China
No. 87 Xiangya Road Furong District, Changsha, China
No.138 Tongzipo Road Yuelu District, Changsha, China
... and 27 other locations.
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Terminated
Last Changed: Sep 16, 2020
First Received: Apr 21, 2017
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): TAK-659
Locations: University of Kansas Medical Center, Westwood, Kansas, United States
University of Michigan, Ann Arbor, Michigan, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
New York University Langone Medical Center, New York, New York, United States
Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
... and 37 other locations.
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jun 16, 2020
First Received: Feb 27, 2017
Disease(s): Diffuse Large B-cell-lymphoma
Intervention(s): Venetoclax, RICE
Locations: Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma
Status: Unknown status
Last Changed: Sep 21, 2018
First Received: Jun 27, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Metformin
Locations: Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo Leon, Mexico
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: Sep 16, 2020
First Received: May 29, 2020
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Community Cancer Institute (CCI), Fresno, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
University of Maryland Medical Center, Baltimore, Maryland, United States
... and 50 other locations.
RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Completed
Last Changed: Apr 02, 2018
First Received: Apr 02, 2018
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): HS006+CHOP, HS006+CHOP, Rituximab+CHOP
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Sep 10, 2020
First Received: Dec 02, 2019
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): Polatuzumab Vedotin, Rituximab, Gemcitabine, Oxaliplatin
Locations: Memorial Regional Hospital, Hollywood, Florida, United States
Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States
Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States
IHA Hematology Oncology Consultants - Ann Arbor; Michigan Orthopedic Center, Ypsilanti, Michigan, United States
Nebraska Cancer Specialists; Oncology Hematology West, PC, Omaha, Nebraska, United States
... and 23 other locations.
Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma
Status: Terminated
Last Changed: Apr 14, 2017
First Received: Mar 27, 2008
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): diffusion MRI
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Oct 08, 2019
First Received: Apr 20, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): 18F-FDG PET SCAN, MRI DIFFUSION
Locations: Centre antoine-LACASSAGNE, Nice, France